Table 1. Patient characteristics compared with respect to major prognostic variables.
| Characteristic | Control | AC | P value |
|---|---|---|---|
| n = | 29 | 45 | N/A |
| Age (years) | |||
| Median | 66 | 70 | 0.04 |
| Range | 49–84 | 53–86 | |
| Gleason score | |||
| 6 | 3 (10.3%) | 2 (4.4%) | 0.52 |
| 7 | 8 (27.6%) | 9 (20%) | |
| 8 | 8 (27.6%) | 17 (38.8%) | |
| 9 | 8 (27.6%) | 16 (35.6%) | |
| 10 | 2 (6.9%) | 1 (2.2%) | |
| Initial PSA | |||
| Mean | 40 | 49 | 0.47 |
| Median | 30.9 | 21.6 | |
| Standard deviation | 33 | 69.6 | |
| Range | 4.7–147 | 1.8–332.7 | |
| Tumor clinical stage | |||
| T1c-T2b | 14 (48.3%) | 23 (51.1%) | 0.81 |
| T2c-T3b | 14 (48.3%) | 20 (44.4%) | |
| Unknown | 1 (3.4%) | 2 (4.4%) | |
| Follow-up (mo) | |||
| Mean | 47 | 53.5 | 0.27 |
| Median | 51.3 | 61.6 | |
| Standard deviation | 26 | 22.2 | |
| Range | 3.2–88.3 | 1.9–81.9 | |
| Pelvic lymphatic irradiation | |||
| Yes | 25 (86.2%) | 40 (89.9%) | 0.73 |
| No | 4 (13.8%) | 5 (11.1%) | |
| Hormone therapy | |||
| Yes | 24 (82.8%) | 40 (95.6%) | 0.36 |
| No | 3 (10.3%) | 2 (4.4%) | |
| Duration of hormone therapy | |||
| None | 3 (10.3%) | 2 (4.4%) | 0.25 |
| <6 mo | 4 (13.8%) | 4 (8.9%) | |
| 6–23 mo | 10 (34.4%) | 12 (26.7%) | |
| ≥24 mo | 10 (34.4%) | 27 (60%) | |
| Unknown | 2 (6.9%) | 0 (0%) |
PSA, prostate specific antigen; AC, anticoagulant; P, P value.